We have further evaluated the efficacy of molecular‐targeted drugs, including the EGFR‐TKI, MET‐TKI, and the tropomyosin‐related kinase (TRK)‐TKI, in our brain tumor models, in comparison to their efficacy in extracranial tumor models, such as subcutaneous tumors, peritoneal carcinomatosis, and liver metastasis models. This evidence concerns the gene NTRK1 and brain neoplasm.